Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov;100(11):e446-9.
doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20.

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Efstathios Kastritis  1 , Marie-Christine Kyrtsonis  2 , Pierre Morel  3 , Maria Gavriatopoulou  4 , Evdoxia Hatjiharissi  5 , Argirios S Symeonidis  6 , Amalia Vassou  7 , Panagiotis Repousis  8 , Sossana Delimpasi  9 , Anastasia Sioni  10 , Evrydiki Michalis  11 , Michail Michael  12 , Elina Vervessou  13 , Michael Voulgarelis  14 , Costantinos Tsatalas  15 , Evangelos Terpos  4 , Meletios A Dimopoulos  4
Affiliations

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Efstathios Kastritis et al. Haematologica. 2015 Nov.
No abstract available

Keywords: Rituximab; age; cyclophosphamide; fludarabine; lymphoma; prognosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival curves (1-survival proportion) with WM-related and non-WM-related deaths as competing events (A) in all patients (B) in patients >75 vs. ≤75 years of age (C) per ISSWM risk group, (D) for patients who received primary therapy with rituximab vs. other agents (alkylators or NAs).
See this image and copyright information in PMC

References

    1. Gertz MA. Waldenstrom macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88(8):703–711. - PubMed
    1. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133(2):158–164. - PubMed
    1. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008;26(24):4027–4034. - PMC - PubMed
    1. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol 2013;66(6):648–653. - PubMed
    1. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30(2):116–120. - PubMed

LinkOut - more resources